The BCL11B Knockout CAL-27 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the CAL-27 human oral squamous cell carcinoma cell line, engineered for loss of BCL11B function. This polyclonal format yields a heterogeneous pool of cells with disrupted BCL11B alleles, capturing the genetic diversity found in tumor populations and avoiding clonal bias. It serves as a robust tool for investigating BCL11B??s regulatory roles in oral cancer biology.
Host cell line CAL-27 is a well-established model of tongue squamous cell carcinoma, displaying aggressive growth, epithelial morphology, and mutant p53. Its tumorigenic properties, including rapid proliferation and invasive potential, make it ideal for functional genomics in head and neck cancers. The lingual origin provides direct relevance to studying BCL11B??s functions in oral epithelial dynamics and malignant transformation.
BCL11B encodes a zinc-finger transcriptional repressor that recruits the NuRD complex containing HDAC1, HDAC2, and MTA2 to gene promoters, where it mediates deacetylation and gene silencing. It operates downstream of NOTCH1/RBPJ and TCR signaling cascades involving LCK, ZAP70, and NFAT, and is modulated by NF-??B and MAP kinase pathways. BCL11B directly represses target genes including CDKN2B, IL-2, CD4, CD8, and E2F1, thereby controlling cell cycle progression and apoptosis. Interactions with BRCA1 and p53 link BCL11B to genome stability and tumor suppression. Knockout of BCL11B disrupts these repressive complexes, leading to derepression of targets and altered chromatin states.
In the CAL-27 oral cancer model, BCL11B knockout abrogates its context-dependent functions, which span tumor suppression and potentially oncogenic roles. Disruption of BCL11B-mediated chromatin remodeling and Notch pathway crosstalk can impact proliferation, survival, and differentiation of squamous carcinoma cells. By exploring how BCL11B loss influences oncogenic signaling, epithelial-mesenchymal transition, and therapy sensitivity, researchers gain insights into oral carcinogenesis. The polyclonal knockout population further recapitulates tumor heterogeneity, enabling identification of phenotypic variations and therapeutic vulnerabilities.
Applications include T-cell biology studies in epithelial contexts, cancer gene function validation, drug target assessment, and immunotherapy research. Typical assays comprise Western blotting for BCL11B, RT-qPCR for downstream targets (e.g., CDKN2B, IL-2), RNA-seq, flow cytometry, proliferation and apoptosis assays, ChIP-qPCR for histone modifications, and co-immunoprecipitation for NuRD complex interactions. This model also supports investigation of BCL11B??s role in chromatin architecture and epigenetic regulation. For further information, please contact Ascent Research.
